Abstract
Objective: To evaluate the expression of antibodies against calretinin, cytokeratin 5/6, desmin, D2-40, HBME-1, mesothelin, thrombomodulin, WT1, Ber-EP4, CEA, EMA and MOC-31 individually and to compare it with a new rapid procedure for fluorescence immunocytochemistry (ICC) using liquid-based cytology (LBC). Study Design: Sixty-four peritoneal cell specimens prepared with the LBC method were stained with these markers to evaluate their usefulness and develop a rapid fluorescence immunostaining method using Ber-EP4 that is applicable to intraoperative cancer cytodiagnosis. Results: The adenocarcinoma markers were positive in 92% of adenocarcinoma cases, 57% of cases with suspicion of adenocarcinoma, and 5% of negative cases (reactive mesothelial cells). On the other hand, the mesothelial cell markers were positive in 8-15% of adenocarcinoma cases, 43-57% of cases with suspicion of adenocarcinoma, and 93-95% of negative cases. The rapid new fluorescence ICC procedure clearly stained only the adenocarcinoma cells within 20 min. Conclusion: Immunocytochemical examination with the LBC method is a powerful ancillary technique for discriminating adenocarcinoma cells from mesothelial cells. This rapid new fluorescence ICC procedure can be used as an ancillary technique for accurate detection of adenocarcinoma cells in the intraoperative cytological examination of peritoneal or pleural washing fluid.
Journal Section:
Editor's choice
References
1.
Morgan RL, De Young BR, McGaughy VR, Niemann TH: MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999;87:390-394.
[PubMed]
2.
Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H: Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-155.
[PubMed]
3.
Attanoos RL, Griffin A, Gibbs AR: The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231-238.
[PubMed]
4.
Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, ed 14. Tokyo, Kanehara, 2010.
5.
Grefte JM, de Wilde PC, Salet-van de Pol MR, et al: Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions. Acta Cytol 2008;52:35-44.
[PubMed]
6.
Bernstein SJ, Sanchez-Ramos L, Ndubisi B: Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308-317.
[PubMed]
7.
Nasuti JF, Tam D, Gupta PK: Diagnostic value of liquid-based (ThinPrep) preparations in nongynecologic cases. Diagn Cytopathol 2001;24:137-141.
[PubMed]
8.
Sakakibara E, Kimachi S, Hashimoto K, et al: An aspiration material preparation system: application of a new liquid-based cytology technique for fine-needle aspiration of the breast. Acta Cytol 2011;55:92-99.
[PubMed]
9.
Delahaye M, van der Ham F, van der Kwast TH: Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997;17:115-120.
[PubMed]
10.
Ordóñez NG: The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
[PubMed]
11.
Saad RS, Cho P, Liu YL, Silverman JF: The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005;32:156-159.
[PubMed]
12.
Ordóñez NG: Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998;29:166-169.
[PubMed]
13.
González-Lois C, Ballestín C, Sotelo MT, et al: Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-534.
[PubMed]
14.
Kennedy AD, King G, Kerr KM: HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol 1997;50:859-862.
[PubMed]
15.
Ordóñez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-1428.
[PubMed]
16.
Fetsch PA, Simsir A, Abati A: Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001;25:158-161.
[PubMed]
17.
Ordóñez NG: D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372-380.
[PubMed]
18.
Koide K, Sakakura C, Hagiwara A, et al: An improved rapid procedure for fluorescence in situ hybridization that is applicable to intraoperative cancer cytodiagnosis. Cancer Lett 2000;158:165-169.
[PubMed]
19.
Mönig SP, Luebke T, Soheili A, et al: Rapid immunohistochemical detection of tumor cells in gastric carcinoma. Oncol Rep 2006;16:1143-1147.
[PubMed]
20.
Furuhata A, Sueyoshi N, Kurihara H, et al: Rapid multiple immunocytochemical staining method using microwave irradiation for intraoperative cytology. Acta Cytol 2010;54:283-290.
[PubMed]
21.
Denda T, Kamoshida S, Kawamura J, et al: Rapid immunocytochemistry with simple heat-induced antigen retrieval technique for improvement in the quality of cytological diagnosis. J Histochem Cytochem 2013;61:920-930.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
